Search PubMed⌕ Search

Biomedical subjects

T Yoshimasa

Publications and source records attributed to T Yoshimasa.

At least 73 records · Page 4Linked to original sources

Effects of repetitive administration of corticotropin-releasing hormone combined with lysine vasopressin on plasma adrenocorticotropin and cortisol levels in secondary adrenocortical insufficiency.

To examine the functioning of the hypothalamo-pituitary-adrenocortical axis in secondary adrenocortical insufficiency, we administered 100 micrograms synthetic human CRH, iv, plus 10 U lysine-8-vasopressin (LVP), im, three times daily for 3 consecutive days. The changes in plasma ACTH and cortisol levels during the administration and the response to an insulin tolerance test (ITT) conducted before and after the administration were determined. In three patients with isolated ACTH deficiency, basal plasma ACTH and cortisol levels were undetectablly low, and there was no response noted in the ITT or during CRH-LVP administration throughout the observation period. In four patients with adrenocortical insufficiency who had undergone successful transsphenoidal microadenomectomy for Cushing's disease and in six patients who had undergone curative unilateral adrenalectomy for Cushing's syndrome, basal plasma ACTH levels were low, but responded considerably to both stimulation tests. Along with the 3 days of CRH-LVP stimulation, however, neither the peak nor the time-integrated ACTH response was significantly enhanced, because of the variability of the responses among the patients. Compared with the ACTH response on the last day of CRH-LVP stimulation, the subsequent ITT tended to induce a lower ACTH response in the post-Cushing's disease patients and a higher response in the post-Cushing's syndrome patients. Regarding the plasma cortisol levels, the basal, peak, and integrated responses tended to increase daily during CRH-LVP administration. Conversely, the ITT after repetitive CRH-LVP administration induced a higher cortisol response than the test before CRH-LVP administration in the post-Cushing's disease patients. No serious complications were noted in any of the patients during or after the treatment. The present findings indicate that 1) repetitive administration of CRH in combination with LVP is a safe and valuable provocation test to examine the pituitary ACTH reserve and the integrity of the pituitary-adrenocortical axis; 2) isolated ACTH deficiency is usually due to a defect at the pituitary level; 3) with respect to adrenocortical responsiveness, post-Cushing's disease patients show a better accumulation of the provocative effect than do post-Cushing's syndrome patients; and 4) both hypothalamic and pituitary dysfunction are responsible for adrenal hypofunction in patients after hypercortisolemia, but post-Cushing's syndrome patients (especially those with a short period of hypercortisolemia) appeared to have less impairment of hypothalamic ACTH-releasing activity than post-Cushing's disease patients.

Adrenal Cortex↗

Phosphorylation of the mammalian beta-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein.

In some systems, such as the turkey erythrocyte, agonist-promoted phosphorylation of the beta-adrenergic receptor appears to be associated with desensitization of the adenylate cyclase system. This process can be partially mimicked by cyclic AMP analogs. Accordingly, we have investigated the phosphorylation of the pure mammalian beta-adrenergic receptor by the pure catalytic subunit of the cyclic AMP-dependent protein kinase. The beta-adrenergic receptor, purified from hamster lung to apparent homogeneity, contains a single polypeptide of Mr approximately 64,000. The receptor can be phosphorylated in vitro by the catalytic subunit of cyclic AMP-dependent protein kinase (approximately 2 mol of phosphate (on serine residues) per mol). Isoproterenol, a beta-agonist, promoted a 2-3-fold increase in the rate of receptor phosphorylation which was blocked by the beta-antagonists propranolol and alprenolol. High performance liquid chromatographic tryptic peptide mapping reveals two major phosphorylation sites. Phosphorylated receptor can be completely dephosphorylated by a high molecular weight phosphoprotein phosphatase. The rate of receptor dephosphorylation is enhanced 2-3-fold by isoproterenol and this effect is blocked by alprenolol. The functional significance of receptor phosphorylation was examined using ligand binding and reconstitution techniques. While the binding of isoproterenol and alprenolol to the receptor was unaffected by phosphorylation, the ability of the receptor to interact with the stimulatory guanine nucleotide regulatory protein, as assessed by isoproterenol-promoted GTPase activity, was decreased 24 +/- 1% (mean +/- S.E., p less than 0.001, n = 17). The quantitative extent of receptor phosphorylation and functional impairment are virtually identical to those previously observed when intact turkey erythrocytes were incubated with cyclic AMP. These data provide a direct demonstration of regulation of the function of the isolated beta-adrenergic receptor by cyclic AMP-dependent protein kinase.

Animals↗

Leumorphin in human brain.

Porcine leumorphin, a putative opioid peptide corresponding to amino acid residues 228-256 of preproenkephalin B has been demonstrated to exist in the porcine neurointermediate pituitary. A recent study on the sequence analysis of genomic DNA of human preproenkephalin B has shown that human leumorphin differs in 3 amino acid residues from porcine leumorphin. In order to clarify whether leumorphin is an endogenous opioid peptide in man, we have studied its existence and regional distribution in the human brain using a radioimmunoassay (RIA) for leumorphin. Reverse-phase HPLC and high performance gel permeation chromatography coupled with the RIA for leumorphin revealed that human leumorphin existed together with rimorphin (dynorphin B) in water extracts of the human brain. Leumorphin-like immunoreactivity (-LI) and dynorphin-LI distributed in parallel throughout the brain. These results indicate that leumorphin is a novel endogenous opioid peptide in man.

Animals↗

Endogenous opioids and related peptides: from molecular biology to clinical medicine. The Sir Henry Dale lecture for 1985.

Advances in techniques in molecular biology have facilitated the research into endogenous opioids and related peptides in several ways. The organization and expression of genes and the primary structure of three precursor proteins of opioid peptides have been elucidated. These studies predicted the presence of potentially bioactive peptides, which has been confirmed by later studies. Advances in techniques in protein chemistry have helped to elucidate the distribution and molecular forms of endogenous opioids and related peptides in the body, and the processing of precursor proteins. Studies on the function of these peptides have shown a broad spectrum of actions. Leumorphin, a newly identified peptide, has been shown to exhibit unique biological activities. In spite of extensive studies, the physiological and pathophysiological significance of opioid peptide systems are not yet completely understood. This is mainly due to the paucity of our knowledge about opioid receptors. Further studies on the subtypes of opioid receptors will help to elucidate all aspects of the function of endogenous opioids and related peptides.

Animals↗

Human leumorphin is a potent, kappa opioid receptor agonist.

The opioid activity and opioid receptor type specificity of synthetic human leumorphin were studied in vitro. Human leumorphin inhibited the contraction of the myenteric plexus-longitudinal muscle preparation of the guinea pig ileum and was similar in opioid potency to porcine leumorphin. This action of human leumorphin was antagonized less effectively by naloxone than by the opiate antagonist Mr 2266. Human leumorphin also inhibited the contraction of the rabbit vas deferens which has only the kappa-type opioid receptor. It is concluded that human leumorphin has potent opioid activity and acts as an agonist at the kappa-type opioid receptor, like porcine leumorphin and other peptides derived from preproenkephalin B.

Animals↗

Leumorphin is a novel endogenous opioid peptide in man.

Porcine leumorphin, a putative opioid peptide corresponding to amino acid residues 228-256 of preproenkephalin B has been demonstrated to exist in the porcine neurointermediate pituitary. A recent study on the sequence analysis of genomic DNA of human preproenkephalin B has shown that human leumorphin differs in 3 amino acid residues from porcine leumorphin. In order to clarify whether leumorphin is an endogenous opioid peptide in man, we have studied its existence in the human brain using a radioimmunoassay and its opioid activity by a bioassay with the guinea-pig ileum myenteric plexus-longitudinal muscle preparation. High performance gel permeation chromatography and reverse-phase high performance liquid chromatography coupled with the radioimmunoassay for leumorphin have revealed that human leumorphin exists in water extracts of the human striatum. In the guinea-pig ileum assay, synthetic human leumorphin exhibited potent opioid activity, with the concentration of 3nM to give 50 per cent inhibition. These results indicate that leumorphin is a novel endogenous opioid peptide in man.

Adult↗

Demonstration and characterization of immunoreactive methionine-enkephalin, leucine-enkephalin, methionine-enkephalin-Arg6-Gly7-Leu8 and methionine-enkephalin-Arg6-Phe7 in human phaeochromocytoma.

To elucidate whether or not human phaeochromocytoma contains methionine-enkephalin-Arg6-Gly7-Leu8 (Met-enkephalin-Arg-Gly-Leu) and methionine-enkephalin-Arg6-Phe7 (Met-enkephalin-Arg-Phe) together with methionine-enkephalin (Met-enkephalin) and leucine-enkephalin (Leu-enkephalin), all of which are known to exist in the same precursor molecule (preproenkephalin A), we examined extracts from 16 phaeochromocytomas using high performance liquid chromatography (HPLC) and gel exclusion chromatography coupled with radioimmunoassays (RIAs) for these four opioid peptides. Met-enkephalin-Arg-Gly-Leu-like immunoreactivity (-LI) and Met-enkephalin-Arg-Phe-LI existed together with Met-enkephalin-LI and Leu-enkephalin-LI in 16 phaeochromocytomas. There was a wide variation in contents of Met-enkephalin-LI, Leu-enkephalin-LI, Met-enkephalin-Arg-Gly-Leu-LI and Met-enkephalin-Arg-Phe-LI. Significant positive correlations were observed among the contents of these four opioid peptides in 16 phaeochromocytomas. HPLC and gel exclusion chromatography followed by the RIAs showed the presence of Met-enkephalin, Leu-enkephalin, Met-enkephalin-Arg-Gly-Leu and Met-enkephalin-Arg-Phe together with their high molecular weight forms, which existed in variable amounts. Molar ratios of the contents of these four opioid peptides determined after HPLC varies from case to case. These results indicate the co-existence of Met-enkephalin, Leu-enkephalin, Met-enkephalin-Arg-Gly-Leu and Met-enkephalin-Arg-Phe in human phaeochromocytomas, suggesting the preservation of amino acid sequences of these four opioid peptides even in neoplastic tissues.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗

Leumorphin is a novel endogenous opioid peptide derived from preproenkephalin B.

Using synthetic leumorphin, we obtained antisera for leumorphin and set up two radioimmunoassays (RIAs) with different specificities. Gel exclusion chromatography coupled with the two RIAs showed the existence of a considerable amount of leumorphin-like peptide in water extracts from porcine neuro-intermediate pituitaries. Reverse phase high performance liquid chromatography revealed that leumorphin-like peptide in the water extracts was indistinguishable from synthetic leumorphin. These results along with potent opioid activity of leumorphin indicate that leumorphin is a novel endogenous opioid peptide derived from preproenkephalin B.

Animals↗

A novel opioid peptide, leumorphin, acts as an agonist at the kappa opiate receptor.

The primary structure of the common precursor of porcine beta-neo-endorphin and dynorphin (preproenkephalin B) has shown the existence of a third leucine-enkephalin (leu-enkephalin) sequence with a C-terminal extension of 24 amino acids. This nonacosapeptide, named leumorphin, was approximately 70 times more potent than leu-enkephalin in inhibiting the contraction of the myenteric plexus-longitudinal muscle preparation of the guinea pig ileum. This action of leumorphin, like those of beta-neo-endorphin and dynorphin, was antagonized less effectively by naloxone than that of leu-enkephalin, but more effectively by Mr2266, an antagonist relatively specific for the kappa type opiate receptor. The inhibitory action of leumorphin or beta-neo-endorphin on the contraction of the guinea pig ileum muscle strip was reduced in a dose-dependent manner by pretreatment with dynorphin and vice versa. Leumorphin as well as beta-neo-endorphin and dynorphin inhibits the contraction of the rabbit vas deferens which is known to have only the kappa type opiate receptor. This action was also effectively antagonized by Mr2266. It is concluded that leumorphin has potent opioid activity and acts at the kappa receptor, like other opioid peptides derived from preproenkephalin B.

Animals↗

Rimorphin (dynorphin B) exists together with alpha-neo-endorphin and dynorphin (dynorphin A) in human hypothalamus.

Rimorphin (dynorphin B) has been demonstrated to exist together with alpha-neo-endorphin and dynorphin(1-17) (dynorphin A) in the human hypothalamus. The content of rimorphin was comparable to that of alpha-neo-endorphin and somewhat higher than that of dynorphin. This result is quite similar to the recent observations in bovine, porcine and rat neural tissues, suggesting that rimorphin is derived from preproenkephal in B together with alpha-neo-endorphin and dynorphin in man.

Adult↗

Biosynthesis and distribution of opioid peptides.

Group III opioid peptides are derived from proenkephalin B. The processing of this precursor peptide is still only partly understood and we still do not know how many final products come from proenkephalin B and whether Leu-enkephalin is produced from Group III peptides. However, potent biologic activity of Group III opioid peptides and existence of opiate-receptors specific for these peptides (k receptors) strongly suggest that Group III opioid peptides are not precursors of Leu-enkephalin but bioactive substances per se. Further studies should clarify details of the processing of proenkephalin B.

Adrenal Medulla↗

Parallel distribution of methionine-enkephalin-Arg6-Gly7-Leu8 with methionine-enkephalin, leucine-enkephalin and methionine-enkephalin-Arg6-Phe7 in human and bovine brains.

Using specific radioimmunoassays(RIAs) for methionine-enkephalin(Met-Enk), leucine-enkephalin(Leu-Enk), methionine-enkephalin-Arg6-Gly7-Leu8 (Met-Enk-Arg-Gly-Leu) and methionine-enkephalin-Arg6-Phe7 (Met-Enk-Arg-Phe), we studied the regional distribution of these opioid peptides in human and bovine brains. Met-Enk-Arg-Gly-Leu was distributed in parallel with Met-Enk, Leu-Enk and Met-Enk-Arg-Phe in human and bovine brains. The ratios of molar concentrations of these peptides are almost constant in various regions of human and bovine brains and similar to the ratio of these peptides contained in preproenkephalin A. Gel exclusion chromatography and HPLC coupled with respective RIAs showed the existence of authentic peptides without any detectable high molecular weight forms. These results indicate the parallel distribution of Met-Enk-Arg-Gly-Leu with Met-Enk, Leu-Enk and Met-Enk-Arg-Phe in various regions of human and bovine brains and further suggest that these opioid peptides are derived from the same precursor as that in the adrenal medulla and that the processing of preproenkephalin A is almost complete in human and bovine brains.

Animals↗

Met-enkephalin-Arg6-Gly7-Leu8 exists together with Met-enkephalin-Arg6-Phe7, Met-enkephalin and Leu-enkephalin in human stomach.

Studies on the nucleotide sequence of cloned DNA complementary to mRNA for preproenkephalin A from adrenal medulla and human pheochromocytoma have revealed that this precursor contains 4 copies of methionine-enkephalin(Met-Enk) and one copy each of leu-enkephalin (Leu-Enk), methionine-enkephalin-Arg6-Gly7-Leu8(Met-Enk-Arg6-Gly7-Leu8) and methionine-enkephalin-Arg6-Phe7(Met-Enk-Arg6-Phe7). We have demonstrated the existence of Met-Enk-Arg6-Gly7-Leu8 together with Met-Enk, Leu-Enk and Met-Enk-Arg6-Phe7 in human gastric antrum, using high performance liquid chromatography(HPLC) coupled with radioimmunoassays for these opioid peptides. The ratio of molar concentrations of these peptides in human gastric antrum is almost equal to the ratio of these peptides contained in preproenkephalin A. Furthermore, gel filtration studies on Sephadex G-50 showed that most of immunoreactivities of these peptides were eluted at the elution position of each synthetic peptide without any detectable immunoreactivities at high molecular weight positions. In addition, most of immunoreactivities of these four opioid peptides were detected in the muscular layer of the gastric antrum. These results indicate the presence of Met-Enk-Arg6-Gly7-Leu8 together with Met-Enk, Leu-Enk, and Met-Enk-Arg6-Phe7 in human gastric antrum and further suggest that these opioid peptides are derived from the same precursor as preproenkephalin A in the adrenal medulla and the processing of preproenkephalin A is almost completed in the human stomach.

Chromatography, Gel↗

Methionine-enkephalin, leucine-enkephalin methionine-enkephalin-Arg6-Phe7 and methionine-enkephalin-Arg6-Gly7-Leu8 in human pheochromocytoma.

Methionine-enkephalin(met-enkephalin)-, leucine-enkephalin(leu-enkephalin)-, methionine-enkephalin-Arg6-Phe7(met-enkephalin-Arg-Phe)- and methionine-enkephalin-Arg6-Gly7-Leu8(met-enkephalin-Arg-Gly-Leu)-like immunoreactivities(-LI) were studied in 16 pheochromocytomas by radioimmunoassays (RIAs) for these four opioid peptides. Met-enkephalin-Arg-Phe-LI and met-enkephalin-Arg-Gly-Leu-LI existed together with met-enkephalin-LI and leu-enkephalin-LI in 16 pheochromocytomas. Significant positive correlations were observed among contents of these four opioid peptides in 16 pheochromocytomas. The concentrations of these four opioid peptides in epinephrine producing pheochromocytomas were much higher than those in norepinephrine producing tumors. HPLC and gel exclusion chromatography followed by the RIAs showed the presence of met-enkephalin, leu-enkephalin, met-enkephalin-Arg-Phe and met-enkephalin-Arg-Gly-Leu together with their high molecular weight forms. These results indicate the co-existence of met-enkephalin, leu-enkephalin, met-enkephalin-Arg-Phe, met-enkephalin-Arg-Gly-Leu and their high molecular weight forms derived from preproenkephalin A in human pheochromocytomas and suggest the association of preproenkephalin A synthesis with epinephrine production in human pheochromocytomas.

Adrenal Gland Neoplasms↗

Comparison of the action of putative endogenous kappa-agonists, leumorphin and rimorphin in vitro.

Leumorphin and rimorphin (dynorphin B) were nearly equipotent in inhibiting the contraction of the myenteric plexus-longitudinal muscle preparation of the guinea pig ileum and the rabbit vas deferens. Leumorphin had long duration of action in vitro after wash-out, whereas the duration of action of rimorphin was relatively shorter. These action of leumorphin and rimophin were antagonized less effectively by naloxone than by Mr2266, an antagonist relatively specific for the kappa-receptor. Rimorphin as well as leumorphin inhibits the contraction of the rabbit vas deferens which contains solely kappa-receptors. It is concluded that leumorphin and rimorphin have equipotent opioid activity and act at the kappa-receptor, like other opioid peptides derived from preproenkephalin B.

Animals↗